What is BioLife Solutions's market cap?

BioLife Solutions (BLFS) has a market capitalization of $1.8B and trades on NASDAQ.

What is BioLife Solutions's revenue and profitability?

BioLife Solutions generated $102.8M in trailing twelve-month revenue with net income of $31.1M, representing a net margin of -68.7%. Gross margin stands at 67.2%, with free cash flow of $17.8M. The latest reported period is Q2 2026.

Who are BioLife Solutions's competitors?

BioLife Solutions's key competitors include Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Techne Corp., and others. These companies compete in similar markets and product categories.

Who does BioLife Solutions partner with?

BioLife Solutions's notable partners include Alliance for Regenerative Medicine.

What subsidiaries does BioLife Solutions have?

BioLife Solutions's subsidiaries include PanTHERA CryoSolutions Inc., Arctic Solutions, Inc., Global Cooling, Inc., and others.

Where is BioLife Solutions headquartered?

BioLife Solutions is headquartered in United States of America and employs approximately 414 people. It has been publicly traded since 1989.

BioLife Solutions (BLFS) Stock Fundamentals & Financials

BioLife Solutions is a life sciences company that develops and manufactures bioproduction tools and services specifically for the cell and gene therapy (CGT) industry.

Market cap

$1.77B+44.1%

Revenue$102.8M+25.4%

Net income$31.1M+194%

Free cash flow$17.8M+117%

EPS (diluted)$0.61+186%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 6, 2026

Revenue$28.5MBeat by $669.6K EPS$0.91Beat by $0.88

Read the full report

Next report

Nov 5, 2026 (in 2 months)

Revenue estimate$29.2M

EPS estimate$0.01

Financials

Q2 2026

Income statement

See full

Revenue$28.5M+21.5%

Gross profit$18.3M+20.0%

Operating income$1.7M+111%

Net income$45.1M+385%

EPS (diluted)$0.91+376%

Balance sheet

See full

Cash & equivalents$24.0M-24.8%

Total debt$15.7M-33.9%

Total equity$420.0M+21.0%

Total assets$447.5M+15.6%

Cash flow

See full

Operating cash flow$6.3M-13.8%

CapEx$1.0M-40.2%

Free cash flow$5.3M-5.7%

Valuation & ratios

Valuation

See full

Market cap$1.77B+44.1%

Enterprise value$1.76B+44.4%

P/E56.9×—

P/S17.2×+2.2×

Profitability

See full

Operating margin1.6%—

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio9.7×+5.3×

Competitors

By market cap

Thermo Fisher Scientific$239.76B+34.3%

Danaher$146.47B+6.0%

Revvity$16.3B+64.1%

TEC

Bio-Techne Corp.$11.3B+41.5%

BioLife Solutions$1.8B+44.1%

Azenta$1.5B+4.2%

CryoPort, Inc.$836.2M+88.3%

Impact BioMedical$53.7M-18.7%

By revenue growth

BioLife Solutions+25.4%

CryoPort, Inc.+12.1%

Thermo Fisher Scientific+5.6%

Bio-Techne Corp.-0.4%

By net margin

CryoPort, Inc.41.39%+109pp

Danaher15.95%+1.7pp

Thermo Fisher Scientific15.19%0.0pp

TEC

Bio-Techne Corp.14.97%+4.2pp

Revvity8.16%-2.0pp

Azenta-20.02%-1.3pp

BioLife Solutions-68.71%+70.6pp

Profile

BioLife Solutions is a life sciences company that develops and manufactures bioproduction tools and services specifically for the cell and gene therapy (CGT) industry. The company's core value proposition lies in its proprietary biopreservation media and cell processing technologies that mitigate cell damage during manufacturing, distribution, and transportation. By improving post-preservation cell viability and function, their products help de-risk the commercialization of biologic-based therapies.

Competitive position

A leading provider of cGMP-grade biopreservation media with a significant presence in the CGT clinical trial workflow, supported by over 750 FDA Master File cross-references.

GeographiesUnited States, Europe, Middle East, Africa

Customer segmentsBiopharma, Regenerative Medicine, Clinical Research

Business modelManufacturing, B2B, Direct Sales

SuppliersMulti-compendial raw material suppliers, Contract manufacturing organizations (CMOs), Specialized chemical and synthetic component providers

CustomersRegenerative medicine companies, Cell therapy manufacturers, Hospital-based clinical researchers, Third-party medical distributors

CountryUnited States of America

Listed1989

Employees414.0

CEORoderick de Greef

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitebiolifesolutions.com

FilingsSEC EDGAR

FAQ

What is BioLife Solutions's market cap?: BioLife Solutions (BLFS) has a market capitalization of $1.8B and trades on NASDAQ.
What is BioLife Solutions's revenue and profitability?: BioLife Solutions generated $102.8M in trailing twelve-month revenue with net income of $31.1M, representing a net margin of -68.7%. Gross margin stands at 67.2%, with free cash flow of $17.8M. The latest reported period is Q2 2026.
Who are BioLife Solutions's competitors?: BioLife Solutions's key competitors include Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Techne Corp., and others. These companies compete in similar markets and product categories.
Who does BioLife Solutions partner with?: BioLife Solutions's notable partners include Alliance for Regenerative Medicine.
What subsidiaries does BioLife Solutions have?: BioLife Solutions's subsidiaries include PanTHERA CryoSolutions Inc., Arctic Solutions, Inc., Global Cooling, Inc., and others.
Where is BioLife Solutions headquartered?: BioLife Solutions is headquartered in United States of America and employs approximately 414 people. It has been publicly traded since 1989.

Ask your AI about BioLife Solutions.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude